



Príomhoifigeach Cliniciúil
Oifig an Phríomhoifigigh Cliniciúil

Ospidéal Dr Steevens, Lána Steevens
Baile Átha Cliath 8 , D08 W2A8

Chief Clinical Officer
Office of the Chief Clinical Officer

Dr Steevens Hospital, Steevens Lane
Dublin 8, D08 W2A8

www.hse.ie
[@hselive](https://twitter.com/hselive)

t 01 635 2000
e cco@hse.ie

BY EMAIL ONLY

Deputy David Cullinane
Dáil Éireann
Leinster House
Kildare Street
Dublin 2

3rd June 2022

PQ27583/22 Deputy David Cullinane - To ask the Minister for Health the status of the availability of Evusheld to immunocompromised patients in Ireland; and if he will make a statement on the matter.

Dear Deputy Cullinane,

Thank you for your representation.

The National Centre for Pharmacoeconomics (NCPE) performed a Rapid Review of Evusheld which recommended the development of a Health Technology Assessment (HTA). This is the standard approval process for all new therapeutics which is being progressed for this therapeutic agent.

Once complete, the results of the HTA will be circulated to the COVID-19 Therapeutics Advisory Group (TAG) for consideration. TAG will review the findings of the HTA before making recommendations regarding Evusheld.

I hope this provides you with assistance.

Yours sincerely

Sharon Hayden
General Manager
Office of the CCO